Loading
Six years after brentuximab vedotin for relapsed anaplastic large cell lymphoma, no one in the study had progressed after 40 months, and one in seven was still in remission with no further treatment of any kind.
The final report of the pivotal phase 2 study (NCT00866047) of brentuximab vedotin in relapsed or refractory systemic anaplastic large cell lymphoma, after a median observation of about six years from first treatment, on the durability of remission, progression-free and overall survival, and safety in all 58 enrolled patients.
The authors conclude that single-agent brentuximab vedotin may be a potentially curative treatment option for a subset of people with relapsed systemic ALCL. The evidence for that is eight patients in remission without further treatment, in a single-arm study.
Shares Brentuximab vedotin phase 2 in relapsed systemic anaplastic large cell lymphoma (SG035-0004), ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, Brentuximab vedotin and the tag lymphoma-evidence-entities.
Shares ALK-positive anaplastic large cell lymphoma and the tag lymphoma-evidence-entities.
Shares ALK-positive anaplastic large cell lymphoma and the tag lymphoma-evidence-entities.
Shares Brentuximab vedotin phase 2 in relapsed systemic anaplastic large cell lymphoma (SG035-0004), ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, Brentuximab vedotin.
Shares ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, Brentuximab vedotin.
Shares ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma.
Shares ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, Brentuximab vedotin.
Shares ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/